Cargando…

The risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer

The effect of thyroid stimulating endocrine (TSH) suppression medical aid on bone mineral density (BMD) of patients with differentiated thyroid carcinoma (DTC) or differentiated thyroid malignant neoplastic disease is still controversial. Our aim was to investigate the effect of TSH suppression ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Yang, Li, Bin, Wang, Xiaodong, Mao, Jingxin, Zhang, Yanyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726344/
https://www.ncbi.nlm.nih.gov/pubmed/36482589
http://dx.doi.org/10.1097/MD.0000000000031991
_version_ 1784844757898362880
author Zou, Yang
Li, Bin
Wang, Xiaodong
Mao, Jingxin
Zhang, Yanyan
author_facet Zou, Yang
Li, Bin
Wang, Xiaodong
Mao, Jingxin
Zhang, Yanyan
author_sort Zou, Yang
collection PubMed
description The effect of thyroid stimulating endocrine (TSH) suppression medical aid on bone mineral density (BMD) of patients with differentiated thyroid carcinoma (DTC) or differentiated thyroid malignant neoplastic disease is still controversial. Our aim was to investigate the effect of TSH suppression therapy on BMD of patients with DTC. METHODS: A total of 1651 DTC patients with TSH-suppression medical care were analyzed by RevMan 5.3 software (https://training.cochrane.org/online-learning/core-software/revman/revman-5-download) in the present study. The PubMed and Embase databases were consistently hunted for works revealed through July 29, 2022. RESULTS: The results indicated that a significant association between femoral bone mineral density (FN-BMD) (P = .02) or lumbar spine bone mineral density (L-BMD) (P = .04) and DTC patients with TSH-suppression therapy. However, the total hip bone mineral density (TH-BMD) was not significantly related to DTC patients with TSH-suppression therapy (P = .11). For premenopausal women, it was shown that TH-BMD (P = .02) or L-BMD (P = .01) were closely related to DTC patients with TSH-suppression therapy. However, there was no relationship between FN-BMD and DTC patients with TSH-suppression therapy (P = .06). For postmenopausal women, TH-BMD was closely related to DTC patients with TSH-suppression therapy (P = .02). It was revealed that there was no significant difference between L-BMD (P = .16) or FN-BMD (P = .26) and DTC patients with TSH-suppression therapy. For men, there was no relationship between FN-BMD (P = .94) or L-BMD (P = .29) and DTC patients with TSH-suppression therapy. CONCLUSION: Our systematic review has demonstrated that TSH inhibition treatment mainly influence the TH-BMD or L-BMD of the DTC patients who were premenopausal women; the TH-BMD of the DTC patients who were postmenopausal women. In addition, there was no influence on the FN-BMD or L-BMD of the DTC patients who were men.
format Online
Article
Text
id pubmed-9726344
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-97263442022-12-09 The risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer Zou, Yang Li, Bin Wang, Xiaodong Mao, Jingxin Zhang, Yanyan Medicine (Baltimore) 4300 The effect of thyroid stimulating endocrine (TSH) suppression medical aid on bone mineral density (BMD) of patients with differentiated thyroid carcinoma (DTC) or differentiated thyroid malignant neoplastic disease is still controversial. Our aim was to investigate the effect of TSH suppression therapy on BMD of patients with DTC. METHODS: A total of 1651 DTC patients with TSH-suppression medical care were analyzed by RevMan 5.3 software (https://training.cochrane.org/online-learning/core-software/revman/revman-5-download) in the present study. The PubMed and Embase databases were consistently hunted for works revealed through July 29, 2022. RESULTS: The results indicated that a significant association between femoral bone mineral density (FN-BMD) (P = .02) or lumbar spine bone mineral density (L-BMD) (P = .04) and DTC patients with TSH-suppression therapy. However, the total hip bone mineral density (TH-BMD) was not significantly related to DTC patients with TSH-suppression therapy (P = .11). For premenopausal women, it was shown that TH-BMD (P = .02) or L-BMD (P = .01) were closely related to DTC patients with TSH-suppression therapy. However, there was no relationship between FN-BMD and DTC patients with TSH-suppression therapy (P = .06). For postmenopausal women, TH-BMD was closely related to DTC patients with TSH-suppression therapy (P = .02). It was revealed that there was no significant difference between L-BMD (P = .16) or FN-BMD (P = .26) and DTC patients with TSH-suppression therapy. For men, there was no relationship between FN-BMD (P = .94) or L-BMD (P = .29) and DTC patients with TSH-suppression therapy. CONCLUSION: Our systematic review has demonstrated that TSH inhibition treatment mainly influence the TH-BMD or L-BMD of the DTC patients who were premenopausal women; the TH-BMD of the DTC patients who were postmenopausal women. In addition, there was no influence on the FN-BMD or L-BMD of the DTC patients who were men. Lippincott Williams & Wilkins 2022-12-02 /pmc/articles/PMC9726344/ /pubmed/36482589 http://dx.doi.org/10.1097/MD.0000000000031991 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 4300
Zou, Yang
Li, Bin
Wang, Xiaodong
Mao, Jingxin
Zhang, Yanyan
The risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer
title The risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer
title_full The risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer
title_fullStr The risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer
title_full_unstemmed The risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer
title_short The risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer
title_sort risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer
topic 4300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726344/
https://www.ncbi.nlm.nih.gov/pubmed/36482589
http://dx.doi.org/10.1097/MD.0000000000031991
work_keys_str_mv AT zouyang theriskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer
AT libin theriskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer
AT wangxiaodong theriskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer
AT maojingxin theriskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer
AT zhangyanyan theriskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer
AT zouyang riskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer
AT libin riskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer
AT wangxiaodong riskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer
AT maojingxin riskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer
AT zhangyanyan riskbetweenthyrotropinsuppressionandbonemineraldensityindifferentiatedthyroidcancer